Sustained Effectiveness of Rotavirus Vaccine Against Very Severe Rotavirus Disease Through the Second Year of Life, Bolivia 2013-2014

Clinical Infectious Diseases

Volumn 62, Issue , 2016, Pages S115-S120

  Pringle, Kimberly D ^a,b   Patzi, Maritza ^c   Tate, Jacqueline E ^a   Iniguez Rojas, Volga ^d   Patel, Manish ^a   Inchauste Jordan, Lucia ^d   Montesano, Raul ^e   Zarate, Adolfo ^c   De Oliveira, Lucia ^f   Parashar, Umesh ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Laboratorio Nacional de Virología   (Costa Rica)

^d UNIVERSIDAD MAYOR DE SAN ANDRÉS   (Bolivia)

^e PAN AMERICAN HEALTH ORGANIZATION   (Bolivia)

^f PAN AMERICAN HEALTH ORGANIZATION   (United States)

Author keywords

childhood mortality; diarrhea; gastroenteritis; middle income country; rotavirus

Indexed keywords

ROTAVIRUS VACCINE; LIVE VACCINE; VACCINE;

ARTICLE; BOLIVIA; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; FECES ANALYSIS; FEMALE; GENOTYPE; GROUPS BY AGE; HUMAN; INFANT; INFECTIOUS DIARRHEA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; ROTAVIRUS INFECTION; SCORING SYSTEM; VESIKARI SCORE; CHILDHOOD MORTALITY; DIARRHEA; FECES; GASTROENTERITIS; IMMUNIZATION; IMMUNOLOGY; ROTAVIRUS INFECTIONS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; VACCINATION; VACCINE IMMUNOGENICITY; VIROLOGY;

BOLIVIA; CASE-CONTROL STUDIES; CHILD MORTALITY; CHILD, PRESCHOOL; DIARRHEA; FECES; FEMALE; GASTROENTERITIS; GENOTYPE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGENICITY, VACCINE; INFANT; MALE; MODELS, STATISTICAL; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION; VACCINE POTENCY; VACCINES, ATTENUATED;

EID: 84965144166     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ1026     Document Type: Article

References (20)

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385:117-71.
2. World Health Organization. Immunization, vaccines and biologicals. Available at: http://www.who.int/immunization/diseases/rotavirus/en/. Accessed 29 April 2015.
3. Payne DC, Boom JA, Staat MA, et al. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. Clin Infect Dis 2013; 57:13-20.
4. Cortese MM, Immergluck LC, Held M, et al. Effectiveness of monovalent and pentavalent rotavirus vaccine. Pediatrics 2013; 132:e25-33.
5. Patel M, Pedreira C, De Oliveira LH, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009; 301:2243-51.
6. de Palma O, Cruz L, Ramos H, et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ 2010; 340:c2825.
7. Gastanaduy PA. Effectiveness of rotavirus vaccination against severe childhood diarrhea- Guatemala, 2012. In: Epidemic Intelligence Service Conference, Atlanta, GA, 2014.
8. De Oliveira LH, Giglio N, Ciapponi A, et al. Temporal trends in diarrhea-related hospitalizations and deaths in children under age 5 before and after the introduction of the rotavirus vaccine in four Latin American countries. Vaccine 2013; 31(suppl 3):C99-108.
9. Richardson V, Parashar U, Patel M. Childhood diarrhea deaths after rotavirus vaccination in Mexico. N Engl J Med 2011; 365:772-3.
10. World Bank. Country and lending groups. Available at: http://data.worldbank.org/about/country-and-lending-groups#Lower-middle-income. Accessed 29 April 2015.
11. Patel MM, Patzi M, Pastor D, et al. Effectiveness of monovalent rotavirus vaccine in Bolivia: case-control study. BMJ 2013; 346:f3726.
12. World Health Organization. Generic protocols for (i) hospital-based surveillance to estimate the burden of rotavirus gastroeteritis in children and (ii) a communitybased survey on utilization of health care services for gastroenteritis in children: field test version. Available at: http://www.who.int/immunization/diseases/rotavirus/generic-protocols/en/. Accessed 6 October 2015.
13. Hull JJ, Teel EN, Kerin TK, et al. United States rotavirus strain surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. Pediatr Infect Dis J 2011; 30(suppl 1):S42-7.
14. de Oliveira LH, Camacho LA, Coutinho ES, Ruiz-Matus C, Leite JP. Rotavirus vaccine effectiveness in Latin American and Caribbean countries: A systematic review and meta-analysis. Vaccine 2015; 33(suppl 1):A248-54.
15. Patel MM, Parashar UD. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs. J Infect Dis 2009; 200(suppl 1):S291-9.
16. do Carmo GM, Yen C, Cortes J, et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: A time-series analysis. PLoS Med 2011; 8:e1001024.
17. Yen C, Figueroa JR, Uribe ES, et al. Monovalent rotavirus vaccine provides protection against an emerging fully heterotypic G9P[4] rotavirus strain in Mexico. J Infect Dis 2011; 204:783-6.
18. Correia JB, Patel MM, Nakagomi O, et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P [4] strains in Brazil. J Infect Dis 2010; 201:363-9.
19. Leshem E, Lopman B, Glass R, et al. Distribution of rotavirus strains and strainspecific effectiveness of the rotavirus vaccine after its introduction: A systematic review and meta-analysis. Lancet Infect Dis 2014; 14:847-56.
20. Snelling TL, Schultz R, Graham J, et al. Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting. Clin Infect Dis 2009; 49:428-31.